Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...

Feb 10 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis drugs and ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.

Vertex reports Q4 earnings Monday, with Wall Street expecting $4.03 EPS and $2.78 billion revenue. Strong technicals support VRTX stock, but selling pressure and pipeline execution remain key ...